Show Nav →

Overview Data source: UniProt

Official Gene Symbol Other Aliases
IPO5 KPNB3, RANBP5
Sequence Length (AA) Molecular Weight (Da)
1097 123630
Protein Name
Importin-5
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MAAAAAEQQQ FYLLLGNLLS PDNVVRKQAE ETYENIPGQS KITFLLQAIR
60 70 80 90 100
NTTAAEEARQ MAAVLLRRLL SSAFDEVYPA LPSDVQTAIK SELLMIIQME
110 120 130 140 150
TQSSMRKKVC DIAAELARNL IDEDGNNQWP EGLKFLFDSV SSQNVGLREA
160 170 180 190 200
ALHIFWNFPG IFGNQQQHYL DVIKRMLVQC MQDQEHPSIR TLSARATAAF
210 220 230 240 250
ILANEHNVAL FKHFADLLPG FLQAVNDSCY QNDDSVLKSL VEIADTVPKY
260 270 280 290 300
LRPHLEATLQ LSLKLCGDTS LNNMQRQLAL EVIVTLSETA AAMLRKHTNI
310 320 330 340 350
VAQTIPQMLA MMVDLEEDED WANADELEDD DFDSNAVAGE SALDRMACGL
360 370 380 390 400
GGKLVLPMIK EHIMQMLQNP DWKYRHAGLM ALSAIGEGCH QQMEGILNEI
410 420 430 440 450
VNFVLLFLQD PHPRVRYAAC NAVGQMATDF APGFQKKFHE KVIAALLQTM
460 470 480 490 500
EDQGNQRVQA HAAAALINFT EDCPKSLLIP YLDNLVKHLH SIMVLKLQEL
510 520 530 540 550
IQKGTKLVLE QVVTSIASVA DTAEEKFVPY YDLFMPSLKH IVENAVQKEL
560 570 580 590 600
RLLRGKTIEC ISLIGLAVGK EKFMQDASDV MQLLLKTQTD FNDMEDDDPQ
610 620 630 640 650
ISYMISAWAR MCKILGKEFQ QYLPVVMGPL MKTASIKPEV ALLDTQDMEN
660 670 680 690 700
MSDDDGWEFV NLGDQQSFGI KTAGLEEKST ACQMLVCYAK ELKEGFVEYT
710 720 730 740 750
EQVVKLMVPL LKFYFHDGVR VAAAESMPLL LECARVRGPE YLTQMWHFMC
760 770 780 790 800
DALIKAIGTE PDSDVLSEIM HSFAKCIEVM GDGCLNNEHF EELGGILKAK
810 820 830 840 850
LEEHFKNQEL RQVKRQDEDY DEQVEESLQD EDDNDVYILT KVSDILHSIF
860 870 880 890 900
SSYKEKVLPW FEQLLPLIVN LICPHRPWPD RQWGLCIFDD VIEHCSPASF
910 920 930 940 950
KYAEYFLRPM LQYVCDNSPE VRQAAAYGLG VMAQYGGDNY RPFCTEALPL
960 970 980 990 1000
LVRVIQSADS KTKENVNATE NCISAVGKIM KFKPDCVNVE EVLPHWLSWL
1010 1020 1030 1040 1050
PLHEDKEEAV QTFNYLCDLI ESNHPIVLGP NNTNLPKIFS IIAEGEMHEA
1060 1070 1080 1090 1097
IKHEDPCAKR LANVVRQVQT SGGLWTECIA QLSPEQQAAI QELLNSA

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-226 Collapse assay details

Data source: Panorama

Official Gene Symbol
IPO5
Peptide Sequence
ITFLLQAIR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
42
Peptide End
50
CPTAC ID
CPTAC-226
Peptide Molecular Mass
1,073.6597
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
cell line lysate pool
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C,15N
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y7 (1+) 6.9 7 6.2 12.6 14.1 10 14.4 15.7 11.8 15 25 15
y6 (1+) 7.1 9.9 5.4 17.9 13.6 12.9 19.3 16.8 14 15 25 15
y5 (1+) 9.8 8.3 5.7 17.6 12.3 11.5 20.1 14.8 12.8 15 25 15
sum 6.4 6.7 5.2 14.8 11.7 10.3 16.1 13.5 11.5 15 25 15

Additional Resources and Comments